PATENT CLAIM ANALYSIS

Application Number: 16032858
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-03
Patent Classification: ["544", "405000"]

Abstract:
A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.

Claim (Index 4):
The dry powder pharmaceutical formulation according to  claim 1 , wherein the formulation comprises magnesium stearate.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 95.0
- Lexical Diversity: 1.5
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15457810', '14622368', '15849987', '15253141', '15812425']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8014163767369733
- 35 USC 102 Novelty (BERT): 0.6152638222000287
- Combined Prediction Score: 0.7828011212832788
- Mean Citation Score: 458.30173600000006
- Max Citation Score: 532.753
- Similarity Product: 528.7631673938034

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test